Radnor-based drug developer Certara is selling its regulatory and medical writing business for up to $135 million to Veristat, writes John George for Philadelphia Business Journal.
The medical writing business prepares official documents needed to get drugs approved.
Veristat provides outsourced research and development services to help bring drugs and therapies to market.
An agreement on the sale was reached Wednesday. It is the first major deal to take place under Certara’s new CEO, Jon Resnick.
Resnick is refocusing the company on AI-integrated drug development modeling and simulation.
Certara will receive $100 million from Veristat at closing, expected this quarter, and up to $35 million in payments that will be tied to Veristat’s financial performance, according to federal filings.
Certara’s medical writing business generated $50 million in revenue and $17 million in adjusted profit in 2025. The 220 workers tied to the medical writing business are expected to transfer to Veristat, based in Southborough, Massachusetts after the deal closes.
Resnick took over as CEO on Jan. 1. In a statement, he said going forward the company would focus on math models, simulations and AI tools to help design and test drugs virtually before and alongside human trials.
Read more about Certara’s earnings and clients in the Philadelphia Business Journal.
